Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00236119
Status:
COMPLETED
Last Update Posted:
2012-08-23
First Post:
2005-10-11
Brief Title:
Study of the Efficacy Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis
Sponsor:
Cephalon
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A 12-Week Exploratory Open-Label Nonrandomized Dose-Escalation Study of the Efficacy Safety and Tolerability of Oral CEP-701 in Patients With Severe Recalcitrant Plaque Type Psoriasis
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 12-Week Exploratory Open-Label Nonrandomized Dose-Escalation Study of the Efficacy Safety and Tolerability of Oral CEP-701 in Patients with Severe Recalcitrant Plaque Type Psoriasis
Detailed Description:
A 12-Week Exploratory Open-Label Nonrandomized Dose-Escalation Study of the Efficacy Safety and Tolerability of Oral CEP-701 in Patients with Severe Recalcitrant Plaque Type Psoriasis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None